Healthcare Business

145922793

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Amgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue ...
Read Full Story »
Ebola Virus

Big News for Ebola Stocks

Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks. NewLink Genetics Corp. (NASDAQ: ...
Read Full Story »
health care

5 Health Care Stocks That Need to Play Serious Catch Up

2014 has been another amazing year for stocks, and now the bull market is closer to being six years old and stocks have risen some 200% from the inflection bottom ...
Read Full Story »
biotech

4 More Biotech Stocks to Buy, With Up to 200% Upside

As the Stifel health care conference continues to roll along, the analysts are getting more and more data on the top companies they cover, and many have exciting clinical and ...
Read Full Story »
Biotechnology word cloud

4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential

In the world of biotech investing, there are some sure-fire ways for stocks to move. Pipeline announcements, clinical data and regulatory approval all can move the needle as catalysts for ...
Read Full Story »
153576724

Is Orexigen Really Worth Over 50% More?

Merrill Lynch has released an analyst report that sees more than 50% upside for Orexigen Therapeutics Inc. (NASDAQ: OREX). The top analyst on the call was Steve Byrne, and the general ...
Read Full Story »
145922793

Is This the Sunesis Resurrection?

In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately ...
Read Full Story »
Botox injection

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Botox maker Allergan Inc. (NYSE: AGN), which has fended off offers up to about $173 per share from Valeant Pharmaceuticals International Inc. (NYSE: VRX), announced Monday morning that it has ...
Read Full Story »
DNA

Juno Therapeutics Files for IPO

Juno Therapeutics Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given in the filing, but it is valued ...
Read Full Story »
biotech

What Licensing Imetelstat Will Mean for Geron

Geron Corp. (NASDAQ: GERN) has announced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat. What investors need to keep ...
Read Full Story »
ReWalk

ReWalk Earnings Shine Spotlight on Robotics

Exoskeleton maker ReWalk Robotics Ltd. (NASDAQ: RWLK) reported quarterly earnings Thursday morning for the first time since the company’s initial public offering in mid-September. The Israel-based company posted third-quarter sales ...
Read Full Story »
biotech

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

One sad trend that has exploded in the new millennium has been the increase in hepatitis C cases in the Unites States and around the world. One startling fact is ...
Read Full Story »
Ebola Virus

Ebola Stock Short Interest Surprise

Fears of Ebola seem to have petered out at the end of October and into November. Some of the related stocks had been heavily shorted as they were considered by ...
Read Full Story »
462542665

Gilead Sees Large Insider Stock Sale Into Debt Offering

Gilead Sciences Inc. (NASDAQ: GILD) has become the largest biotech now. The company has run into controversy of late over the pricing of its hepatitis C drug, but it has ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific (Updated)

The short interest data are out for the October 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »